Оптимальный режим двойной антиагрегантной терапии у пациентов с хронической ишемической болезнью сердца (обзор литературы)

Оптимальный режим двойной антиагрегантной терапии у пациентов с хронической ишемической болезнью сердца (обзор литературы)

Автор: Горгулько А. П., Баранов А. А., Хелимский Д. А., Крестьянинов О. В., Бадоян А. Г.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 4 т.38, 2023 года.

Бесплатный доступ

В настоящее время пациентам, которым было выполнено чрескожное коронарное вмешательство (ЧКВ) со стентированием, рекомендован прием двойной антиагрегантной терапии (ДААТ) с целью профилактики тромбоза имплантируемого стента и потенциальных ишемических событий в отдаленном периоде. Однако выбор оптимальных сроков ДААТ после ЧКВ - это до сих пор сложная и актуальная проблема для лечащего врача. Увеличение продолжительности ДААТ после ЧКВ коррелирует с более низкой частотой ишемических событий. В то же время при более длительном режиме ДААТ имеет место более значительное увеличение рисков послеоперационных кровотечений. Исходя из этого, важно найти баланс между потенциальными рисками кровотечений и ожидаемой пользой в снижении ишемических событий, при этом учитывая индивидуальные клинические особенности каждого пациента. Методы внутрисосудистой визуализации, а именно внутрисосудистая когерентная томография, позволяют получить высокоинформативную прижизненную морфологическую оценку состояния коронарных артерий, степень формирования неоинтимы и мальпозицию имплантированного стента, что, в свою очередь, может помочь в выборе оптимальных сроков ДААТ и профилактике нежелательных побочных событий.

Еще

Двойная антиагрегантная терапия, хроническая ишемическая болезнь сердца, оптическая когерентная томография

Короткий адрес: https://sciup.org/149144445

IDR: 149144445   |   DOI: 10.29001/2073-8552-2023-38-4-70-76

Список литературы Оптимальный режим двойной антиагрегантной терапии у пациентов с хронической ишемической болезнью сердца (обзор литературы)

  • Bittl J.A., Baber U., Bradley S.M., Wijeysundera D.N. Duration of dual antiplatelet therapy: a systematicreview for the 2016 ACC/AHA guideline focusedupdate on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2016;68(10):1116-1139. https://doi.org/10.1016/j.jacc.2016.03.512.
  • Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur. Heart J. 2013;34(39):3028-3034. https://doi.org/10.1093/eurheartj/eht356.
  • Frigoli E., Smits P., Vranckx P., Ozaki Y., Tijssen J., Jüni P. et. al. Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study. Am. Heart J. 2019;209:97-105. https://doi.org/10.1016/j.ahj.2018.10.009.
  • Urban P., Mehran R., Colleran R., Angiolillo D.J., Byrne R.A., Capodanno D. et. al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur. Heart J. 2019;40(31):2632-2653. https://doi.org/10.1093/eurheartj/ehz372.
  • Stone G.W., Rizvi A., Newman W., Mastali K., Wang J.C., Caputo R. et. al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 2010;362(18):1663-1674. https://doi.org/10.1056/NEJMoa0910496.
  • Stefanini G.G., Holmes D.R. Jr. Drug-eluting coronary-artery stents. N. Engl. J. Med. 2013;368(3):254-265. https://doi.org/10.1056/NEJMra1210816.
  • Varenne O., Cook S., Sideris G., Kedev S., Cuisset T., Carrié D. et al. Drugeluting stents in elderly patients with coronary artery disease (SENIOR): a randomised singleblind trial. Lancet. 2018;391(10115):41-50. https://doi.org/10.1016/S0140-6736(17)32713-7.
  • Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 2017;377(16):1513-24. https://doi.org/10.1056/NEJMoa1708454.
  • Valgimigli M., Bueno H., Byrne R.A., Collet J.Ph., Costa F., Jeppsson A. et. al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018;39(3):213-260. https://doi.org/10.1093/eurheartj/ehx419.
  • Kim B.K., Hong M.K., Shin D.H., Nam C.M., Kim J.S., Ko Y.G. et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal safety and efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation). J. Am. Coll. Cardiol. 2012;60(15):1340-1348. https://doi.org/10.1016/j.jacc.2012.06.043.
  • Feres F., Costa R.A., Abizaid A., Leon M.B., Marin-Neto J.A., Botelho R.V. et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510-2522. https://doi.org/10.1001/jama.2013.282183.
  • De Luca G., Damen S.A., Camaro C., Benit E., Verdoia M., Rasoul S. et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treat ed with a new-generation stent (REDUCE trial). EuroIntervention. 2019;15(11):e990-e998. https://doi.org/10.4244/eij-d-19-00539.
  • Windecker S., Latib A., Kedhi E., Kirtane A.J., Kandzari D.E., Mehran R. et. al. Polymer-based or polymer-free stents in patients at high bleeding risk. N. Engl. J. Med. 2020;382(13):1208-1218. https://doi.org/10.1056/NEJMoa1910021.
  • Urban P., Meredith I.T., Abizaid A., Pocock S.J., Carrié D., Naber C. et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N. Engl. J. Med. 2015;373(21):2038-2047. https://doi.org/10.1056/NEJMoa1503943.
  • Valgimigli M., Cao D., Makkar R.R., Bangalore S., Bhatt D.L.,Angiolillo D.J. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. Am. Heart J. 2021;231:147-156. https://doi.org/10.1016/j.ahj.2020.09.019.
  • Krucoff M.W., Rutledge D.R., Gruberg L., Jonnavithula L., Katopodis J.N., Lombardi W. et. al. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc. Interv. 2011;4(12):1298-1309. https://doi.org/10.1016/j.jcin.2011.08.010.
  • Барбараш О.Л., Кашталап В.В. Продолжительность двойной антитромбоцитарной терапии. Факты и предположения. Российский кардиологический журнал. 2016;(130): 75-83. https://doi.org/10.15829/1560-4071-2016-2-75-83.
  • Karjalainen P.P., Varho V., Nammas W., Mikkelsson J., Pietilä M., Ylitalo A. et al. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome - HATTRICK-OCT trial. Circ. J. 2015;79(2):360-367. https://doi.org/10.1253/circj.CJ14-1000.
  • Giustino G., Baber U., Sartori S., Mehran R., Mastoris I., Kini A.S. et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and metaanalysis of randomized controlled trials. J. Am. Coll. Cardiol. 2015;65(13):1298-1310. https://doi.org/10.1016/j.jacc.2015.01.039.
  • Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G. et al. (for the DAPT Study Investigators). Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 2014;371(23):2155-2166. https://doi.org/10.1056/NEJMoa1409312.
  • Fanari Z., Malodiya A., Weiss S.A., Hammami S., Kolm P., Weintraub WS. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. Cardiovasc. Revasc. Med. 2017;18(1):10-15. https://doi.org/10.1016/j.carrev.2016.07.006.
  • Serruys P.W., Takahashi K., Chichareon P., Kogame N., Tomaniak M., Modolo R. et. al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019;40(31):2595-2604. https://doi.org/10.1093/eurheartj/ehz453.
  • Giustino G., Chieffo A., Palmerini T., Valgimigli M., Feres F., Abizaid A. et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol. 2016;68(17):1851-1864. https://doi.org/10.1016/j.jacc.2016.07.760.
  • Baber U., Kini A.S., Sharma S.K. Stenting of complex lesions: an overview. Nat. Rev. Cardiol. 2010;7(9):485-496. https://doi.org/10.1038/nrcardio.2010.116.
  • Suh J., Park D.W., Lee J.Y., Jung I.H., Lee S.W., Kim Y.H. et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc. Interv. 2010;3(4):383-389. https://doi.org/10.1016/j.jcin.2009.10.033.
  • Piccolo R., Giustino G., Mehran R., Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386(9994):702-713. https://doi.org/10.1016/S0140-6736(15)61220-X.
  • Jang W.J., Ahn S.G., Song Y.B., Choi S.-H., Chun W.J., Oh J.H. et. al. Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the coronary bifurcation stenting registry II. Circ. Cardiovasc. Interv. 2018;11(7):e005849. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005849.
  • Lee S.H., Yang J.H., Choi S.H., Song Y.B., Hahn J.Y., Choi J.H. et. al. Long-term clinical outcomes of medical therapy for coronary chronic total occlusions in elderly patients (≥ 75 Years). Circ. J. 2015;79(8):1780- 1786. https://doi.org/10.1253/circj.CJ-15-0041.
  • Sachdeva A., Hung Y.Y., Solomon M.D., McNulty E.J. Duration of dual antiplatelet therapy after percutaneous coronary intervention for chronic total occlusion. Am. J. Cardiol. 2020;132:44-51. https://doi.org/10.1016/j.amjcard.2020.06.066.
  • Wang H.Y., Wang Y., Yin D., Gao R.L., Yang Y.J., Xu B. et al. Percutaneous coronary intervention complexity and risk of adverse events in relation to high bleeding risk among patients receiving drug-eluting stents: insights from a large single-center cohort study. J. Interv. Cardiol. 2020:2985435. https://doi.org/10.1155/2020/2985435.
  • Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006;48(1):193-202. https://doi.org/10.1016/j.jacc.2006.03.042.
  • Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C. et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-2441. https://doi.org/10.1161/CIRCULATIONAHA.107.693739.
  • Räber L., Mintz G.S., Koskinas K.C., Johnson T.W., Holm N.R., Onuma Y. et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur. Heart J. 2018;39(35):3281-3300. https://doi.org/10.1093/eurheartj/ehy285.
  • Murata A., Wallace-Bradley D., Tellez A., Alviar C., Aboodi M., Sheehy A. et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc. Imaging. 2010;3(1):76-84. https://doi.org/10.1016/j.jcmg.2009.09.018.
  • Won H., Shin D.H., Kim B.K., Mintz G.S., Kim J.S., Ko Y.G. et al. Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. Int. J. Cardiovasc. Imaging. 2013;29(6):1255-1263. https://doi.org/10.1007/s10554-013-0223-9.
  • Goryo Y., Kume T., Ueda T., Watanabe M., Yamada R., Neishi Y. et al. Vascular healing response after everolimus-eluting stent implantation in acute coronary syndrome culprit lesions: comparison with implantation in stable angina pectoris. Acta Cardiol. Sin. 2018;34(2):124-129. https://doi.org/10.6515/ACS.201803_34(2).20171115A.
  • Ueda T., Uemura S., Watanabe M., Dote Y., Goryo Y., Sugawara Y. et al. Thin-cap fibroatheroma and large calcification at the proximal stent edge correlate with a high proportion of uncovered stent struts in the chronic phase. Coron. Artery Dis. 2016; 27(5):376-384. https://doi.org/10.1097/MCA.0000000000000380.
  • Kakizaki R., Minami Y., Hashikata T., Nemoto T., Hashimoto T., Fujiyoshi K. et al. Impact of underlying plaque type on strut coverage in the early phase after drug-eluting stent implantation. Coron. Artery Dis. 2018;29(8):624-631. https://doi.org/10.1097/MCA.0000000000000654.
  • Laine M., Dabry T., Combaret N., Motreff P., Puymirat E., Paganelli F. et al. OCT Analysis of very early strut coverage of the Synergy stent in non-ST segment elevation acute coronary syndrome patients. J. Invasive Cardiol. 2019;31(1):10-14.
  • Asano T., Jin Q., Katagiri Y., Kogame N., Takahashi K., Chang C.C. et al. A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. EuroIntervention. 2018;14(12):e1306-e1315. https://doi.org/10.4244/EIJ-D-18-00461.
  • Hashikata T., Tojo T., Namba S., Kitasato L., Hashimoto T., Kameda R. et al. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 month’ follow-up: an optical coherence tomography study. Heart Vessels. 2016;31(2):206-211. https://doi.org/10.1007/s00380-014-0598-0.
Еще
Статья обзорная
SciUp 2024 © 2024 ©